Last edition
News about "immunotherapies"
Diakonos Oncology Phase II Glioblastoma Trial Cleared to Continue After DSMB Safety Review
Independent safety review clears Diakonos Oncology’s Phase II DOC1021 glioblastoma trial to proceed, with no safety concerns identified to date.
Immunotherapies | 18/02/2026 | By News Bureau | 138
FDA Grants Orphan Drug Status to HanchorBio's HCB101 for Gastric Cancer
The Orphan Drug Status designation to HanchorBio supports development of next-generation CD47–SIRPα immunotherapy for advanced gastric adenocarcinoma across HER2-positive and HER2-negative subtypes.
Immunotherapies | 16/02/2026 | By News Bureau | 119
Inimmune Begins Phase 2 Trial of INI-2004 for Allergic Rhinitis
The randomised, placebo-controlled allergen chamber study will evaluate the safety and efficacy of Inimmune’s immunotherapy candidate INI-2004 in patients exposed to controlled ragweed allergens.
Immunotherapies | 08/01/2026 | By News Bureau | 143
Two ImmunoINSIGHTS contracts signed by Oncimmune
Oncimmune Holdings announces the signing of two new ImmunoINSIGHTS commercial contracts.
Immunotherapies | 15/04/2022 | By Sudeep Soparkar | 711
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy